TREATMENT OPTIONS IN ONCOLOGY:@0.084848:0.038601:0.493541:0.038601:0.493541:0.019343:0.084848:0.019343:0.010019:0.014276:0.012606:0.015487:0.010019:0.021613:0.012606:0.017404:0.010019:0.006515:0.020438:0.013923:0.010019:0.005315:0.020438:0.017404:0.011712:0.006515:0.005315:0.017404:0.006515:0.020438:0.017404:0.019121:0.020438:0.010866:0.020438:0.020508:0.013923
14:@0.023705:0.038809:0.044778:0.038809:0.044778:0.019212:0.023705:0.019212:0.010536:0.010536
HANDBOOK OF ONCOLOGY:@0.084848:0.970015:0.320957:0.970015:0.320957:0.956010:0.084848:0.956010:0.011682:0.012657:0.012657:0.012726:0.009818:0.014864:0.014864:0.010109:0.004738:0.014864:0.008296:0.004738:0.014864:0.012657:0.013906:0.014864:0.007902:0.014864:0.014915:0.010126
7.:@0.084848:0.094740:0.099062:0.094740:0.099062:0.080735:0.084848:0.080735:0.009476:0.004738
Loo SW, Geropantas K, Roques TW. Function-:@0.121195:0.094740:0.475751:0.094740:0.475751:0.080735:0.121195:0.080735:0.007902:0.011203:0.011203:0.002668:0.008518:0.014607:0.004738:0.002673:0.014915:0.011118:0.005078:0.011203:0.011665:0.011682:0.010434:0.005798:0.011682:0.006636:0.002685:0.010109:0.004738:0.002670:0.010382:0.011203:0.011665:0.010399:0.011118:0.006636:0.002685:0.007286:0.015146:0.004738:0.002673:0.008296:0.010399:0.010434:0.011067:0.005798:0.003421:0.011203:0.010398:0.005679
al organ preservation in locally advanced :@0.121195:0.109027:0.480469:0.109027:0.480469:0.095022:0.121195:0.095022:0.011682:0.003421:0.006106:0.011203:0.005148:0.011511:0.011682:0.010434:0.006106:0.011665:0.005080:0.011118:0.006636:0.011118:0.005148:0.009476:0.011682:0.005798:0.003421:0.011203:0.010434:0.006106:0.003421:0.010434:0.006106:0.003421:0.011203:0.011067:0.011682:0.003421:0.003421:0.009168:0.006120:0.011682:0.011716:0.009476:0.011682:0.010434:0.011067:0.011118:0.011716:0.004738
laryngeal squamous cell carcinoma:  is :@0.121195:0.123315:0.480479:0.123315:0.480479:0.109310:0.121195:0.109310:0.003421:0.011682:0.005148:0.009168:0.010434:0.011511:0.011118:0.011682:0.003421:0.014214:0.006636:0.011665:0.010399:0.011682:0.016044:0.011203:0.010399:0.006636:0.014214:0.011067:0.011118:0.003421:0.003421:0.014214:0.011067:0.011682:0.005029:0.011067:0.003421:0.010434:0.011203:0.016044:0.011682:0.004738:0.004738:0.009466:0.003421:0.006636:0.004738
there  a  role  for  induction  chemothera-:@0.121195:0.137602:0.475751:0.137602:0.475751:0.123597:0.121195:0.123597:0.005798:0.010434:0.011118:0.005071:0.011118:0.004738:0.007103:0.011682:0.004738:0.007105:0.005078:0.011203:0.003421:0.011118:0.004738:0.007102:0.005371:0.011203:0.005148:0.004738:0.007100:0.003421:0.010434:0.011716:0.010399:0.011067:0.005798:0.003421:0.011203:0.010434:0.004738:0.007100:0.011067:0.010434:0.011118:0.016044:0.011203:0.005798:0.010434:0.011118:0.005148:0.011657:0.005679
py? :@0.121195:0.151890:0.156875:0.151890:0.156875:0.137885:0.121195:0.137885:0.011665:0.009168:0.010109:0.004738
Clin Oncol (R Coll Radiol).:@0.159372:0.151890:0.382050:0.151890:0.382050:0.137885:0.159372:0.137885:0.013906:0.003421:0.003421:0.010434:0.007252:0.014864:0.010434:0.011067:0.011203:0.003421:0.007242:0.006312:0.010382:0.007242:0.013906:0.011203:0.003421:0.003421:0.007252:0.010382:0.011682:0.011716:0.003421:0.011203:0.003421:0.006312:0.004738
 2013 May; :@0.382050:0.151890:0.480493:0.151890:0.480493:0.137885:0.382050:0.137885:0.007242:0.009476:0.009476:0.009476:0.009476:0.007252:0.015719:0.011682:0.009168:0.004738:0.004738
25(5):298-307.:@0.121195:0.166177:0.234255:0.166177:0.234255:0.152172:0.121195:0.152172:0.009476:0.009476:0.006312:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.004738
8.:@0.084848:0.180465:0.099062:0.180465:0.099062:0.166460:0.084848:0.166460:0.009476:0.004738
Franco  P, Arcadipane F, Ragona  R, :@0.121195:0.180465:0.451328:0.180465:0.451328:0.166460:0.121195:0.166460:0.008296:0.005148:0.011682:0.010434:0.011067:0.011203:0.004738:0.007528:0.008019:0.004738:0.012281:0.012657:0.005029:0.011067:0.011682:0.011716:0.003421:0.011665:0.011682:0.010434:0.011118:0.012281:0.006205:0.004738:0.012281:0.010382:0.011682:0.011511:0.011203:0.010434:0.011682:0.004738:0.007533:0.010382:0.004738:0.004738
et :@0.458871:0.180465:0.480525:0.180465:0.480525:0.166460:0.458871:0.166460:0.011118:0.005798:0.004738
al:@0.121195:0.194752:0.136298:0.194752:0.136298:0.180747:0.121195:0.180747:0.011682:0.003421
. Hematologic toxicity in anal cancer :@0.136298:0.194752:0.480472:0.194752:0.480472:0.180747:0.136298:0.180747:0.004738:0.011374:0.011682:0.011118:0.016044:0.011682:0.005798:0.011203:0.003421:0.011203:0.011511:0.003421:0.011067:0.011374:0.005798:0.011203:0.008210:0.003421:0.011067:0.003421:0.005798:0.009168:0.011374:0.003421:0.010434:0.011374:0.011682:0.010434:0.011682:0.003421:0.011374:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148:0.004738
patients during  combined  chemo-radia-:@0.121195:0.209040:0.475765:0.209040:0.475765:0.195035:0.121195:0.195035:0.011665:0.011682:0.005798:0.003421:0.011118:0.010434:0.005798:0.006636:0.011289:0.011716:0.010399:0.005148:0.003421:0.010434:0.011511:0.004738:0.006539:0.011067:0.011203:0.016044:0.011665:0.003421:0.010434:0.011118:0.011716:0.004738:0.006542:0.011067:0.010434:0.011118:0.016044:0.011203:0.005679:0.005148:0.011682:0.011716:0.003421:0.011682:0.005679
tion: a radiation oncologist  perspective.  :@0.121195:0.223327:0.480489:0.223327:0.480489:0.209322:0.121195:0.209322:0.005798:0.003421:0.011203:0.010434:0.004738:0.010981:0.011682:0.010981:0.005148:0.011682:0.011716:0.003421:0.011682:0.005798:0.003421:0.011203:0.010434:0.010981:0.011203:0.010434:0.011067:0.011203:0.003421:0.011203:0.011511:0.003421:0.006636:0.005798:0.004738:0.006235:0.011665:0.011118:0.005148:0.006636:0.011665:0.011118:0.011067:0.005798:0.003421:0.009476:0.011118:0.004738:0.000000:0.004738
Expert Rev Anticancer Ther.:@0.121195:0.237615:0.348651:0.237615:0.348651:0.223610:0.121195:0.223610:0.009168:0.008210:0.011665:0.011118:0.005148:0.005798:0.004604:0.010382:0.011118:0.009476:0.004618:0.012657:0.010434:0.005798:0.003421:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148:0.004599:0.007286:0.010434:0.011118:0.005148:0.004738
 2017 Apr;17(4): :@0.348615:0.237615:0.480479:0.237615:0.480479:0.223610:0.348615:0.223610:0.004608:0.009476:0.009476:0.009476:0.009476:0.004618:0.012657:0.011665:0.005148:0.004738:0.009476:0.009476:0.006312:0.009476:0.006312:0.004738:0.004738
335-345.:@0.121195:0.251902:0.188467:0.251902:0.188467:0.237897:0.121195:0.237897:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.004738
9.:@0.084848:0.266190:0.099062:0.266190:0.099062:0.252185:0.084848:0.252185:0.009476:0.004738
McCleary NJ, Benson AB 3rd, Dienstmann :@0.121195:0.266190:0.480508:0.266190:0.480508:0.252185:0.121195:0.252185:0.015719:0.011067:0.013906:0.003421:0.011118:0.011682:0.005148:0.009168:0.007184:0.012657:0.008244:0.004738:0.007168:0.009818:0.011118:0.010434:0.006636:0.011203:0.010434:0.007174:0.012657:0.009818:0.007184:0.009476:0.005047:0.011716:0.004738:0.007175:0.012726:0.003421:0.011118:0.010434:0.006636:0.005798:0.016044:0.011682:0.010434:0.010434:0.004738
R. Personalizing adjuvant therapy for stage :@0.121195:0.280771:0.480506:0.280771:0.480506:0.266766:0.121195:0.266766:0.010382:0.004738:0.005097:0.010126:0.011118:0.005148:0.006636:0.011203:0.010434:0.011682:0.003421:0.003421:0.007269:0.003421:0.010434:0.011511:0.005097:0.011682:0.011716:0.003472:0.010399:0.009476:0.011682:0.010434:0.005798:0.005097:0.005798:0.010434:0.011118:0.005148:0.011682:0.011665:0.009168:0.005097:0.005371:0.011203:0.005148:0.005097:0.006636:0.005798:0.011682:0.011511:0.011118:0.004738
II/III colorectal cancer. :@0.121195:0.295353:0.314136:0.295353:0.314136:0.281347:0.121195:0.281347:0.003866:0.003866:0.007475:0.003866:0.003866:0.003866:0.006175:0.011067:0.011203:0.003421:0.011203:0.005078:0.011118:0.011067:0.005798:0.011682:0.003421:0.006175:0.011067:0.011682:0.010434:0.011067:0.011118:0.003888:0.004738:0.004738
Am Soc Clin Oncol :@0.315572:0.295353:0.480493:0.295353:0.480493:0.281347:0.315572:0.281347:0.012657:0.016044:0.006175:0.008518:0.011203:0.011067:0.006175:0.013906:0.003421:0.003421:0.010434:0.006175:0.014864:0.010434:0.011067:0.011203:0.003421:0.004738
Educ Book:@0.121195:0.309934:0.209094:0.309934:0.209094:0.295929:0.121195:0.295929:0.009168:0.011716:0.010399:0.011067:0.004738:0.009818:0.011203:0.011203:0.008586
. 2017;37:232-245.:@0.209094:0.309934:0.352172:0.309934:0.352172:0.295929:0.209094:0.295929:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.004738
10.  Irtan S, Ehrlich PF, Pritchard-Jones K. Wilms :@0.084848:0.324516:0.480486:0.324516:0.480486:0.310510:0.084848:0.310510:0.009476:0.009476:0.004738:0.012657:0.000000:0.003866:0.005148:0.005798:0.011682:0.010434:0.006927:0.008518:0.004738:0.006931:0.009168:0.010434:0.005148:0.003421:0.003421:0.011067:0.010434:0.006934:0.010126:0.006202:0.004738:0.006931:0.010126:0.005148:0.003421:0.005798:0.011067:0.010434:0.011682:0.005037:0.011716:0.005679:0.008244:0.011203:0.010434:0.011118:0.006636:0.006929:0.010109:0.004738:0.006927:0.016519:0.003421:0.003421:0.016044:0.006636:0.004738
tumor: “State-of-the-art” update, 2016. :@0.121195:0.339097:0.449476:0.339097:0.449476:0.325092:0.121195:0.325092:0.005798:0.010399:0.016044:0.011203:0.005148:0.004738:0.005689:0.008586:0.008518:0.005798:0.011682:0.005798:0.011118:0.005679:0.011203:0.005371:0.005679:0.005798:0.010434:0.011118:0.005679:0.011682:0.005148:0.005798:0.008279:0.005692:0.010399:0.011665:0.011716:0.011682:0.005798:0.011118:0.004738:0.005703:0.009476:0.009476:0.009476:0.009476:0.004738:0.004738
Se-:@0.450451:0.339097:0.475765:0.339097:0.475765:0.325092:0.450451:0.325092:0.008518:0.011118:0.005679
min Pediatr Surg.:@0.121195:0.353679:0.259894:0.353679:0.259894:0.339673:0.121195:0.339673:0.016044:0.003421:0.010434:0.004738:0.010126:0.011118:0.011716:0.003421:0.011682:0.005798:0.005148:0.004738:0.008518:0.010399:0.005148:0.011511:0.004738
 2016 Oct;25(5):250-256.:@0.259877:0.353679:0.456783:0.353679:0.456783:0.339673:0.259877:0.339673:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.014864:0.011067:0.005798:0.004738:0.009476:0.009476:0.006312:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.004738
11.  Kris MG, Gaspar LE, Chaft JE, :@0.084848:0.368260:0.385851:0.368260:0.385851:0.354255:0.084848:0.354255:0.009476:0.009476:0.004738:0.012657:0.000000:0.010109:0.005148:0.003421:0.006636:0.009271:0.015719:0.014915:0.004738:0.009271:0.014915:0.011682:0.006636:0.011665:0.011682:0.005148:0.009271:0.007902:0.009168:0.004738:0.009271:0.013906:0.010434:0.011682:0.005371:0.005798:0.009271:0.008244:0.009168:0.004738:0.004738
et al:@0.390384:0.368260:0.431673:0.368260:0.431673:0.354255:0.390384:0.354255:0.011118:0.005798:0.009271:0.011682:0.003421
. Ad-:@0.431673:0.368260:0.475734:0.368260:0.475734:0.354255:0.431673:0.354255:0.004738:0.009271:0.012657:0.011716:0.005679
juvant Systemic Therapy and Adjuvant :@0.121195:0.382842:0.480489:0.382842:0.480489:0.368836:0.121195:0.368836:0.003472:0.010399:0.009476:0.011682:0.010434:0.005798:0.013889:0.008518:0.009168:0.006636:0.005798:0.011118:0.016044:0.003421:0.011067:0.013889:0.007286:0.010434:0.011118:0.005148:0.011682:0.011665:0.009168:0.013889:0.011682:0.010434:0.011716:0.013889:0.012657:0.011716:0.003472:0.010399:0.009476:0.011682:0.010434:0.005798:0.004738
Radiation Therapy for Stage I to IIIA Com-:@0.121195:0.397423:0.475786:0.397423:0.475786:0.383418:0.121195:0.383418:0.010382:0.011682:0.011716:0.003421:0.011682:0.005798:0.003421:0.011203:0.010434:0.006585:0.007286:0.010434:0.011118:0.005148:0.011682:0.011665:0.009168:0.006585:0.005371:0.011203:0.005148:0.006568:0.008518:0.005798:0.011682:0.011511:0.011118:0.006573:0.003866:0.006585:0.005798:0.011203:0.006571:0.003866:0.003866:0.003866:0.012657:0.006577:0.013906:0.011203:0.016044:0.005679
pletely Resected Non-Small-Cell Lung Can-:@0.121195:0.412005:0.475772:0.412005:0.475772:0.397999:0.121195:0.397999:0.011665:0.003421:0.011118:0.005798:0.011118:0.003421:0.009168:0.004345:0.010382:0.011118:0.006636:0.011118:0.011067:0.005798:0.011118:0.011716:0.004345:0.012657:0.011203:0.010434:0.005679:0.008518:0.016044:0.011682:0.003421:0.003421:0.005679:0.013906:0.011118:0.003421:0.003421:0.004345:0.007902:0.010399:0.010434:0.011511:0.004331:0.013906:0.011682:0.010434:0.005679
cers:  American  Society  of  Clinical Oncol-:@0.121195:0.426586:0.475755:0.426586:0.475755:0.412581:0.121195:0.412581:0.011067:0.011118:0.005148:0.006636:0.004738:0.004738:0.003253:0.012657:0.016044:0.011118:0.005148:0.003421:0.011067:0.011682:0.010434:0.004738:0.003255:0.008518:0.011203:0.011067:0.003421:0.011118:0.005798:0.009168:0.004738:0.003257:0.011203:0.005371:0.004738:0.003255:0.013906:0.003421:0.003421:0.010434:0.003421:0.011067:0.011682:0.003421:0.008005:0.014864:0.010434:0.011067:0.011203:0.003421:0.005679
ogy/Cancer Care Ontario Clinical Practice :@0.121195:0.441168:0.480489:0.441168:0.480489:0.427162:0.121195:0.427162:0.011203:0.011511:0.009168:0.007475:0.013906:0.011682:0.010434:0.011067:0.011118:0.005148:0.004327:0.013906:0.011682:0.005080:0.011118:0.004327:0.014864:0.010434:0.005798:0.011682:0.005148:0.003421:0.011203:0.004327:0.013906:0.003421:0.003421:0.010434:0.003421:0.011067:0.011682:0.003421:0.004327:0.010126:0.005148:0.011682:0.011067:0.005798:0.003421:0.011067:0.011118:0.004738
Guideline Update:@0.121195:0.455749:0.271388:0.455749:0.271388:0.441744:0.121195:0.441744:0.014915:0.010399:0.003421:0.011716:0.011118:0.003421:0.003421:0.010434:0.011118:0.007047:0.011203:0.011665:0.011716:0.011682:0.005798:0.011118
. J Clin Oncol:@0.271388:0.455749:0.387681:0.455749:0.387681:0.441744:0.271388:0.441744:0.004738:0.007047:0.008244:0.007047:0.013906:0.003421:0.003421:0.010434:0.007047:0.014864:0.010434:0.011067:0.011203:0.003421
. 2017 Sep :@0.387681:0.455749:0.480474:0.455749:0.480474:0.441744:0.387681:0.441744:0.004738:0.007047:0.009476:0.009476:0.009476:0.009476:0.007066:0.008518:0.011118:0.011665:0.004738
1;35(25):2960-2974.:@0.121195:0.470331:0.276896:0.470331:0.276896:0.456325:0.121195:0.456325:0.009476:0.004738:0.009476:0.009476:0.006312:0.009476:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.009476:0.004738
12.  Sulman EP, Ismaila  N, Armstrong TS, :@0.084848:0.484912:0.450989:0.484912:0.450989:0.470907:0.084848:0.470907:0.009476:0.009476:0.004738:0.012657:0.000000:0.008518:0.010399:0.003421:0.016044:0.011682:0.010434:0.012589:0.009168:0.008020:0.004738:0.012589:0.003866:0.006636:0.016044:0.011682:0.003421:0.003421:0.011682:0.004738:0.007870:0.012657:0.004738:0.012589:0.012657:0.005617:0.016044:0.006636:0.005798:0.005078:0.011203:0.010434:0.011511:0.012589:0.007286:0.008518:0.004738:0.004738
et :@0.458840:0.484912:0.480494:0.484912:0.480494:0.470907:0.458840:0.470907:0.011118:0.005798:0.004738
al:@0.121195:0.499493:0.136298:0.499493:0.136298:0.485488:0.121195:0.485488:0.011682:0.003421
.  Radiation  Therapy  for  Glioblastoma: :@0.136298:0.499493:0.480484:0.499493:0.480484:0.485488:0.136298:0.485488:0.004738:0.004738:0.007991:0.010382:0.011682:0.011716:0.003421:0.011682:0.005798:0.003421:0.011203:0.010434:0.004738:0.007991:0.007286:0.010434:0.011118:0.005148:0.011682:0.011665:0.009168:0.004738:0.007995:0.005371:0.011203:0.005148:0.004738:0.007986:0.014915:0.003421:0.003421:0.011203:0.011665:0.003421:0.011682:0.006636:0.005798:0.011203:0.016044:0.011682:0.004738:0.004738
American Society of Clinical  Oncology :@0.121195:0.514075:0.480505:0.514075:0.480505:0.500070:0.121195:0.500070:0.012657:0.016044:0.011118:0.005148:0.003421:0.011067:0.011682:0.010434:0.013119:0.008518:0.011203:0.011067:0.003421:0.011118:0.005798:0.009168:0.013119:0.011203:0.005371:0.013119:0.013906:0.003421:0.003421:0.010434:0.003421:0.011067:0.011682:0.003421:0.004738:0.008397:0.014864:0.010434:0.011067:0.011203:0.003421:0.011203:0.011511:0.009168:0.004738
Clinical Practice  Guideline Endorsement :@0.121195:0.528656:0.480506:0.528656:0.480506:0.514651:0.121195:0.514651:0.013906:0.003421:0.003421:0.010434:0.003421:0.011067:0.011682:0.003421:0.011870:0.010126:0.005148:0.011682:0.011067:0.005798:0.003421:0.011067:0.011118:0.004738:0.007115:0.014915:0.010399:0.003421:0.011716:0.011118:0.003421:0.003421:0.010434:0.011118:0.011870:0.009168:0.010434:0.011716:0.011203:0.005148:0.006636:0.011118:0.016044:0.011118:0.010434:0.005798:0.004738
of the American Society for Radiation On-:@0.121195:0.543238:0.475751:0.543238:0.475751:0.529233:0.121195:0.529233:0.011203:0.005371:0.006055:0.005798:0.010434:0.011118:0.006055:0.012657:0.016044:0.011118:0.005148:0.003421:0.011067:0.011682:0.010434:0.006055:0.008518:0.011203:0.011067:0.003421:0.011118:0.005798:0.009168:0.006055:0.005371:0.011203:0.005148:0.006055:0.010382:0.011682:0.011716:0.003421:0.011682:0.005798:0.003421:0.011203:0.010434:0.006055:0.014864:0.010434:0.005679
cology Guideline. :@0.121195:0.557819:0.276349:0.557819:0.276349:0.543814:0.121195:0.543814:0.011067:0.011203:0.003421:0.011203:0.011511:0.009168:0.008142:0.014915:0.010399:0.003421:0.011716:0.011118:0.003421:0.003421:0.010434:0.011118:0.004738:0.004738
J Clin Oncol:@0.279752:0.557819:0.386449:0.557819:0.386449:0.543814:0.279752:0.543814:0.008244:0.008142:0.013906:0.003421:0.003421:0.010434:0.008142:0.014864:0.010434:0.011067:0.011203:0.003421
. 2017  Jan :@0.386449:0.557819:0.480488:0.557819:0.480488:0.543814:0.386449:0.543814:0.004738:0.008142:0.009476:0.009476:0.009476:0.009476:0.004738:0.003419:0.008244:0.011682:0.010434:0.004738
20;35(3):361-369.:@0.121195:0.572401:0.257944:0.572401:0.257944:0.558396:0.121195:0.558396:0.009476:0.009476:0.004738:0.009476:0.009476:0.006312:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.004738
13.  Chang JS, Koom WS, Lee Y, :@0.084848:0.586982:0.361010:0.586982:0.361010:0.572977:0.084848:0.572977:0.009476:0.009476:0.004738:0.012657:0.000000:0.013906:0.010434:0.011682:0.010434:0.011511:0.006808:0.008244:0.008518:0.004738:0.006808:0.010109:0.011203:0.011203:0.016044:0.006808:0.016420:0.008518:0.004738:0.006808:0.007902:0.011118:0.011118:0.006808:0.008462:0.004738:0.004738
et al:@0.363080:0.586982:0.401907:0.586982:0.401907:0.572977:0.363080:0.572977:0.011118:0.005798:0.006808:0.011682:0.003421
. Postop-:@0.401907:0.586982:0.475763:0.586982:0.475763:0.572977:0.401907:0.572977:0.004738:0.006808:0.010126:0.011203:0.006636:0.005798:0.011203:0.011665:0.005679
erative adjuvant  chemoradiotherapy  in :@0.121195:0.601564:0.480491:0.601564:0.480491:0.587559:0.121195:0.587559:0.011118:0.005148:0.011682:0.005798:0.003421:0.009476:0.011118:0.013410:0.011682:0.011716:0.003472:0.010399:0.009476:0.011682:0.010434:0.005798:0.004738:0.008682:0.011067:0.010434:0.011118:0.016044:0.011203:0.005148:0.011682:0.011716:0.003421:0.011203:0.005798:0.010434:0.011118:0.005148:0.011682:0.011665:0.009168:0.004738:0.008663:0.003421:0.010434:0.004738
D2-dissected gastric cancer: is radiothera-:@0.121195:0.616145:0.475760:0.616145:0.475760:0.602140:0.121195:0.602140:0.012726:0.009476:0.005679:0.011716:0.003421:0.006636:0.006636:0.011118:0.011067:0.005798:0.011118:0.011716:0.005969:0.011511:0.011682:0.006636:0.005798:0.005148:0.003421:0.011067:0.005959:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148:0.004738:0.005954:0.003421:0.006636:0.005969:0.005148:0.011682:0.011716:0.003421:0.011203:0.005798:0.010434:0.011118:0.005148:0.011682:0.005679
py necessary after D2-dissection? :@0.121195:0.630727:0.409944:0.630727:0.409944:0.616722:0.121195:0.616722:0.011665:0.009168:0.007201:0.010434:0.011118:0.011067:0.011118:0.006636:0.006636:0.011682:0.005148:0.009168:0.007201:0.011682:0.005371:0.005798:0.011118:0.005148:0.007201:0.012726:0.009476:0.005679:0.011716:0.003421:0.006636:0.006636:0.011118:0.011067:0.005798:0.003421:0.011203:0.010444:0.010109:0.004738
World J :@0.412407:0.630727:0.480500:0.630727:0.480500:0.616722:0.412407:0.616722:0.016420:0.011203:0.005148:0.003421:0.011716:0.007201:0.008244:0.004738
Gastroenterol.:@0.121195:0.645308:0.239557:0.645308:0.239557:0.631303:0.121195:0.631303:0.014915:0.011682:0.006636:0.005798:0.005148:0.011203:0.011118:0.010434:0.005798:0.011118:0.005148:0.011203:0.003421:0.004738
 2014 Sep 28;20(36):12900-7.:@0.239540:0.645308:0.469183:0.645308:0.469183:0.631303:0.239540:0.631303:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.008518:0.011118:0.011665:0.004738:0.009476:0.009476:0.004738:0.009476:0.009476:0.006312:0.009476:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476:0.004738
14.  Ives NJ,  Suciu  S,  Eggermont  AMM, :@0.084848:0.659890:0.425810:0.659890:0.425810:0.645884:0.084848:0.645884:0.009476:0.009476:0.004738:0.012657:0.000000:0.003866:0.009476:0.011118:0.006636:0.008980:0.012657:0.008244:0.004738:0.004738:0.004225:0.008518:0.010399:0.011067:0.003421:0.010399:0.004738:0.004233:0.008518:0.004738:0.004738:0.004232:0.009168:0.011511:0.011511:0.011118:0.005615:0.016044:0.011203:0.010434:0.005798:0.004738:0.004225:0.012657:0.015719:0.015719:0.004738:0.004738
et  al:@0.430031:0.659890:0.471017:0.659890:0.471017:0.645884:0.430031:0.645884:0.011118:0.005798:0.004738:0.004228:0.011682:0.003421
. :@0.471017:0.659890:0.480493:0.659890:0.480493:0.645884:0.471017:0.645884:0.004738:0.004738
International:@0.121195:0.674471:0.225985:0.674471:0.225985:0.660466:0.121195:0.660466:0.003866:0.010434:0.005798:0.011118:0.005499:0.010434:0.011682:0.005798:0.003421:0.011203:0.010434:0.011682:0.003421
Melanoma:@0.248186:0.674471:0.339489:0.674471:0.339489:0.660466:0.248186:0.660466:0.015719:0.011118:0.003421:0.011682:0.010434:0.011203:0.016044:0.011682
Meta-Analysis:@0.361691:0.674471:0.475743:0.674471:0.475743:0.660466:0.361691:0.660466:0.015719:0.011118:0.005798:0.011682:0.005679:0.012657:0.010434:0.011682:0.003421:0.009168:0.006636:0.003421:0.006636
Collaborative Group (IMMCG). Adjuvant :@0.121195:0.689053:0.480505:0.689053:0.480505:0.675047:0.121195:0.675047:0.013906:0.011203:0.003421:0.003421:0.011682:0.011665:0.011203:0.005148:0.011682:0.005798:0.003421:0.009476:0.011118:0.010348:0.014915:0.005078:0.011203:0.010399:0.011665:0.010348:0.006312:0.003866:0.015719:0.015719:0.013906:0.014915:0.006312:0.004738:0.010348:0.012657:0.011716:0.003472:0.010399:0.009476:0.011682:0.010434:0.005798:0.004738
interferon-  for  the treatment  of high-risk :@0.121195:0.703634:0.480517:0.703634:0.480517:0.689629:0.121195:0.689629:0.003421:0.010434:0.005798:0.011118:0.005961:0.005371:0.011118:0.005075:0.011203:0.010434:0.005679:0.008946:0.009253:0.005371:0.011203:0.005148:0.004738:0.004504:0.005798:0.010434:0.011118:0.009253:0.005798:0.005075:0.011118:0.011682:0.005798:0.016044:0.011118:0.010434:0.005798:0.004738:0.004505:0.011203:0.005371:0.009253:0.010434:0.003421:0.011511:0.010434:0.005679:0.005148:0.003421:0.006636:0.008586:0.004738
α:@0.206806:0.705280:0.215751:0.705280:0.215751:0.689417:0.206806:0.689417:0.008946
melanoma: an individual  patient data :@0.121195:0.718216:0.480505:0.718216:0.480505:0.704210:0.121195:0.704210:0.016044:0.011118:0.003421:0.011682:0.010434:0.011203:0.016044:0.011682:0.004738:0.014043:0.011682:0.010434:0.014043:0.003421:0.010434:0.011716:0.003421:0.009476:0.003421:0.011716:0.010399:0.011682:0.003421:0.004738:0.009320:0.011665:0.011682:0.005798:0.003421:0.011118:0.010434:0.005798:0.014043:0.011716:0.011682:0.005798:0.011682:0.004738
meta-analysis. :@0.121195:0.732797:0.244073:0.732797:0.244073:0.718792:0.121195:0.718792:0.016044:0.011118:0.005798:0.011682:0.005679:0.011682:0.010434:0.011682:0.003421:0.009168:0.006636:0.003421:0.006636:0.004738:0.004738
Eur J Cancer:@0.246895:0.732797:0.358296:0.732797:0.358296:0.718792:0.246895:0.718792:0.009168:0.010399:0.005148:0.007543:0.008244:0.007543:0.013906:0.011682:0.010434:0.011067:0.011118:0.005148
. 2017  Sep;82: :@0.358296:0.732797:0.480503:0.732797:0.480503:0.718792:0.358296:0.718792:0.004738:0.007543:0.009476:0.009476:0.009476:0.009476:0.004738:0.002819:0.008518:0.011118:0.011665:0.004738:0.009476:0.009476:0.004738:0.004738
171-183.:@0.121195:0.747379:0.188467:0.747379:0.188467:0.733373:0.121195:0.733373:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.004738
15.  Franklin C, Livingstone E, Roesch A, :@0.084848:0.761960:0.428235:0.761960:0.428235:0.747955:0.084848:0.747955:0.009476:0.009476:0.004738:0.012657:0.000000:0.008296:0.005148:0.011682:0.010434:0.008586:0.003421:0.003421:0.010434:0.007748:0.013906:0.004738:0.007748:0.007902:0.003421:0.009476:0.003421:0.010434:0.011511:0.006636:0.005798:0.011203:0.010434:0.011118:0.007748:0.009168:0.004738:0.007748:0.010382:0.011203:0.011118:0.006636:0.011067:0.010434:0.007748:0.012657:0.004738:0.004738
et al:@0.431246:0.761960:0.471013:0.761960:0.471013:0.747955:0.431246:0.747955:0.011118:0.005798:0.007748:0.011682:0.003421
. :@0.471013:0.761960:0.480489:0.761960:0.480489:0.747955:0.471013:0.747955:0.004738:0.004738
Immunotherapy in melanoma: recent ad-:@0.121195:0.776542:0.475755:0.776542:0.475755:0.762536:0.121195:0.762536:0.003866:0.016044:0.016044:0.010399:0.010434:0.011203:0.005798:0.010434:0.011118:0.005148:0.011682:0.011665:0.009168:0.006907:0.003421:0.010434:0.006917:0.016044:0.011118:0.003421:0.011682:0.010434:0.011203:0.016044:0.011682:0.004738:0.006914:0.005077:0.011118:0.011067:0.011118:0.010434:0.005798:0.006910:0.011682:0.011716:0.005679
vances and future directions. :@0.121195:0.791123:0.364977:0.791123:0.364977:0.777118:0.121195:0.777118:0.009476:0.011682:0.010434:0.011067:0.011118:0.006636:0.004002:0.011682:0.010434:0.011716:0.004002:0.005371:0.010399:0.005798:0.010399:0.005071:0.011118:0.004002:0.011716:0.003421:0.005082:0.011118:0.011067:0.005798:0.003421:0.011203:0.010434:0.006636:0.004738:0.004738
Eur J Surg On-:@0.364241:0.791123:0.475762:0.791123:0.475762:0.777118:0.364241:0.777118:0.009168:0.010399:0.005148:0.004002:0.008244:0.004002:0.008518:0.010399:0.005148:0.011511:0.004002:0.014864:0.010434:0.005679
col:@0.121195:0.805705:0.146886:0.805705:0.146886:0.791699:0.121195:0.791699:0.011067:0.011203:0.003421
. 2017 Mar;43(3):604-611.:@0.146886:0.805705:0.349350:0.805705:0.349350:0.791699:0.146886:0.791699:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.015719:0.011682:0.005148:0.004738:0.009476:0.009476:0.006312:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.004738
16.  Burstein HJ, Lacchetti C, Anderson H, :@0.084848:0.820286:0.432997:0.820286:0.432997:0.806281:0.084848:0.806281:0.009476:0.009476:0.004738:0.012657:0.000000:0.009818:0.010399:0.005148:0.006636:0.005798:0.011118:0.003421:0.010434:0.005388:0.011682:0.008244:0.004738:0.005388:0.007902:0.011682:0.011067:0.011067:0.010434:0.011118:0.005798:0.005798:0.003421:0.005388:0.013906:0.004738:0.005388:0.012657:0.010434:0.011716:0.011118:0.005148:0.006636:0.011203:0.010434:0.005378:0.011682:0.004738:0.004738
et al:@0.433647:0.820286:0.471055:0.820286:0.471055:0.806281:0.433647:0.806281:0.011118:0.005798:0.005388:0.011682:0.003421
. :@0.471055:0.820286:0.480530:0.820286:0.480530:0.806281:0.471055:0.806281:0.004738:0.004738
Adjuvant  Endocrine  Therapy  for  Women :@0.121195:0.834868:0.480512:0.834868:0.480512:0.820862:0.121195:0.820862:0.012657:0.011716:0.003472:0.010399:0.009476:0.011682:0.010434:0.005798:0.004738:0.005908:0.009168:0.010434:0.011716:0.011203:0.011067:0.005148:0.003421:0.010434:0.011118:0.004738:0.005906:0.007286:0.010434:0.011118:0.005148:0.011682:0.011665:0.009168:0.004738:0.005904:0.005371:0.011203:0.005148:0.004738:0.005908:0.015633:0.011203:0.016044:0.011118:0.010434:0.004738
With Hormone Receptor-Positive  Breast :@0.121195:0.849449:0.480503:0.849449:0.480503:0.835444:0.121195:0.835444:0.016519:0.003421:0.005798:0.010434:0.015531:0.011682:0.011203:0.005619:0.016044:0.011203:0.010434:0.011118:0.015531:0.010382:0.011118:0.011067:0.011118:0.011665:0.005798:0.011203:0.005148:0.005679:0.010126:0.011203:0.006636:0.003421:0.005798:0.003421:0.009476:0.011118:0.004738:0.010783:0.009818:0.005082:0.011118:0.011682:0.006636:0.005798:0.004738
Cancer: American Society of Clinical On-:@0.121195:0.864030:0.475760:0.864030:0.475760:0.850025:0.121195:0.850025:0.013906:0.011682:0.010434:0.011067:0.011118:0.005148:0.004738:0.007251:0.012657:0.016044:0.011118:0.005148:0.003421:0.011067:0.011682:0.010434:0.007256:0.008518:0.011203:0.011067:0.003421:0.011118:0.005798:0.009168:0.007257:0.011203:0.005371:0.007254:0.013906:0.003421:0.003421:0.010434:0.003421:0.011067:0.011682:0.003421:0.007269:0.014864:0.010434:0.005679
cology Clinical Practice Guideline Update :@0.121195:0.878612:0.480491:0.878612:0.480491:0.864607:0.121195:0.864607:0.011067:0.011203:0.003421:0.011203:0.011511:0.009168:0.005906:0.013906:0.003421:0.003421:0.010434:0.003421:0.011067:0.011682:0.003421:0.005918:0.010126:0.005148:0.011682:0.011067:0.005798:0.003421:0.011067:0.011118:0.005906:0.014915:0.010399:0.003421:0.011716:0.011118:0.003421:0.003421:0.010434:0.011118:0.005910:0.011203:0.011665:0.011716:0.011682:0.005798:0.011118:0.004738
on Ovarian Suppression. :@0.121195:0.893193:0.326340:0.893193:0.326340:0.879188:0.121195:0.879188:0.011203:0.010434:0.005268:0.014864:0.009476:0.011682:0.005148:0.003421:0.011682:0.010434:0.005278:0.008518:0.010399:0.011665:0.011665:0.005082:0.011118:0.006636:0.006636:0.003421:0.011203:0.010434:0.004738:0.004738
J Clin Oncol.:@0.326875:0.893193:0.432563:0.893193:0.432563:0.879188:0.326875:0.879188:0.008244:0.005268:0.013906:0.003421:0.003421:0.010434:0.005268:0.014864:0.010434:0.011067:0.011203:0.003421:0.004738
 2016 :@0.432563:0.893193:0.480472:0.893193:0.480472:0.879188:0.432563:0.879188:0.005268:0.009476:0.009476:0.009476:0.009476:0.004738
May 10;34(14):1689-701.:@0.121195:0.907481:0.318203:0.907481:0.318203:0.893476:0.121195:0.893476:0.015719:0.011682:0.009168:0.004738:0.009476:0.009476:0.004738:0.009476:0.009476:0.006312:0.009476:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.004738
17.  Freedman OC, Fletcher GG, Gandhi S, :@0.084848:0.921768:0.456625:0.921768:0.456625:0.907763:0.084848:0.907763:0.009476:0.009476:0.004738:0.012657:0.000000:0.008296:0.005075:0.011118:0.011118:0.011716:0.016044:0.011682:0.010434:0.006979:0.014864:0.013906:0.004738:0.006979:0.008296:0.003421:0.011118:0.005798:0.011067:0.010434:0.011118:0.005148:0.006963:0.014915:0.014915:0.004738:0.006979:0.014915:0.011682:0.010434:0.011716:0.010434:0.003421:0.006979:0.008518:0.004738:0.004738
et :@0.458866:0.921768:0.480520:0.921768:0.480520:0.907763:0.458866:0.907763:0.011118:0.005798:0.004738
al:@0.121195:0.936056:0.136298:0.936056:0.136298:0.922051:0.121195:0.922051:0.011682:0.003421
. Adjuvant endocrine  therapy for  early :@0.136298:0.936056:0.480503:0.936056:0.480503:0.922051:0.136298:0.922051:0.004738:0.009236:0.012657:0.011716:0.003472:0.010399:0.009476:0.011682:0.010434:0.005798:0.009236:0.011118:0.010434:0.011716:0.011203:0.011067:0.005148:0.003421:0.010434:0.011118:0.004738:0.004488:0.005798:0.010434:0.011118:0.005148:0.011682:0.011665:0.009168:0.009236:0.005371:0.011203:0.005148:0.004738:0.004488:0.011118:0.011682:0.005148:0.003421:0.009168:0.004738
breast cancer: a systematic review of the :@0.560589:0.094881:0.919881:0.094881:0.919881:0.080876:0.560589:0.080876:0.011665:0.005080:0.011118:0.011682:0.006636:0.005798:0.006654:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148:0.004738:0.006654:0.011682:0.006654:0.006636:0.009168:0.006636:0.005798:0.011118:0.016044:0.011682:0.005798:0.003421:0.011067:0.006654:0.005078:0.011118:0.009476:0.003421:0.011118:0.014214:0.006654:0.011203:0.005371:0.006654:0.005798:0.010434:0.011118:0.004738
evidence for the 2014 Cancer Care Ontar-:@0.560589:0.109192:0.915157:0.109192:0.915157:0.095187:0.560589:0.095187:0.011118:0.009476:0.003421:0.011716:0.011118:0.010434:0.011067:0.011118:0.004897:0.005371:0.011203:0.005148:0.004890:0.005798:0.010434:0.011118:0.004897:0.009476:0.009476:0.009476:0.009476:0.004909:0.013906:0.011682:0.010434:0.011067:0.011118:0.005148:0.004892:0.013906:0.011682:0.005078:0.011118:0.004897:0.014864:0.010434:0.005798:0.011682:0.005148:0.005679
io systemic therapy guideline:@0.560589:0.123503:0.806738:0.123503:0.806738:0.109498:0.560589:0.109498:0.003421:0.011203:0.006688:0.006636:0.009168:0.006636:0.005798:0.011118:0.016044:0.003421:0.011067:0.006688:0.005798:0.010434:0.011118:0.005148:0.011682:0.011665:0.009168:0.006688:0.011511:0.010399:0.003421:0.011716:0.011118:0.003421:0.003421:0.010434:0.011118
. Curr Oncol.:@0.806738:0.123503:0.915166:0.123503:0.915166:0.109498:0.806738:0.109498:0.004738:0.006688:0.013906:0.010399:0.005148:0.005148:0.006674:0.014864:0.010434:0.011067:0.011203:0.003421:0.004738
 :@0.915166:0.123503:0.919904:0.123503:0.919904:0.109498:0.915166:0.109498:0.004738
2015 Mar;22(Suppl 1):S95-S113.:@0.560589:0.137814:0.811544:0.137814:0.811544:0.123809:0.560589:0.123809:0.009476:0.009476:0.009476:0.009476:0.004738:0.015719:0.011682:0.005148:0.004738:0.009476:0.009476:0.006312:0.008518:0.010399:0.011665:0.011665:0.003421:0.004738:0.009476:0.006312:0.004738:0.008518:0.009476:0.009476:0.005679:0.008518:0.009476:0.009476:0.009476:0.004738
18.  Trent JC, Subramanian MP. Managing GIST :@0.524242:0.152125:0.919897:0.152125:0.919897:0.138120:0.524242:0.138120:0.009476:0.009476:0.004738:0.012657:0.000000:0.006773:0.005078:0.011118:0.010434:0.005798:0.005473:0.008244:0.013906:0.004738:0.005473:0.008518:0.010399:0.011665:0.005148:0.011682:0.016044:0.011682:0.010434:0.003421:0.011682:0.010434:0.005473:0.015719:0.008568:0.004738:0.005473:0.015719:0.011682:0.010434:0.011682:0.011511:0.003421:0.010434:0.011511:0.005473:0.014915:0.003866:0.008518:0.007286:0.004738
in the imatinib  era: optimization of adju-:@0.560589:0.166436:0.915142:0.166436:0.915142:0.152431:0.560589:0.152431:0.003421:0.010434:0.008980:0.005798:0.010434:0.011118:0.008980:0.003421:0.016044:0.011682:0.005798:0.003421:0.010434:0.003421:0.011665:0.004738:0.004256:0.011118:0.005148:0.011682:0.004738:0.008980:0.011203:0.011665:0.005798:0.003421:0.016044:0.003421:0.007269:0.011682:0.005798:0.003421:0.011203:0.010434:0.008980:0.011203:0.005371:0.008980:0.011682:0.011716:0.003472:0.010399:0.005679
vant therapy. :@0.560589:0.180747:0.679233:0.180747:0.679233:0.166742:0.560589:0.166742:0.009476:0.011682:0.010434:0.005798:0.006765:0.005798:0.010434:0.011118:0.005148:0.011682:0.011665:0.009168:0.004738:0.004738
Expert Rev Anticancer Ther:@0.681260:0.180747:0.910438:0.180747:0.910438:0.166742:0.681260:0.166742:0.009168:0.008210:0.011665:0.011118:0.005148:0.005798:0.006760:0.010382:0.011118:0.009476:0.006765:0.012657:0.010434:0.005798:0.003421:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148:0.006758:0.007286:0.010434:0.011118:0.005148
. :@0.910424:0.180747:0.919900:0.180747:0.919900:0.166742:0.910424:0.166742:0.004738:0.004738
2014 Dec;14(12):1445-59.:@0.560606:0.195058:0.765431:0.195058:0.765431:0.181053:0.560606:0.181053:0.009476:0.009476:0.009476:0.009476:0.004738:0.012726:0.011118:0.011067:0.004738:0.009476:0.009476:0.006312:0.009476:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.004738
19.  André T, Iveson T, Labianca R, :@0.524259:0.209369:0.813604:0.209369:0.813604:0.195364:0.524259:0.195364:0.009476:0.009476:0.004738:0.012657:0.000000:0.012486:0.010263:0.011545:0.004977:0.010947:0.006705:0.005366:0.004567:0.006705:0.003695:0.009305:0.010947:0.006465:0.011032:0.010263:0.006705:0.005366:0.004567:0.006705:0.007731:0.011511:0.011494:0.003250:0.011511:0.010263:0.010895:0.011511:0.006705:0.010211:0.004567:0.004738
et al:@0.815571:0.209369:0.853782:0.209369:0.853782:0.195364:0.815571:0.195364:0.010947:0.005627:0.006705:0.011511:0.003421
 for the :@0.853611:0.209369:0.919974:0.209369:0.919974:0.195364:0.853611:0.195364:0.006705:0.005200:0.011032:0.004977:0.006705:0.005627:0.010263:0.011116:0.004738
IDEA Steering Committee. The IDEA (Inter-:@0.560606:0.223680:0.915179:0.223680:0.915179:0.209675:0.560606:0.209675:0.003695:0.012555:0.008997:0.012486:0.008056:0.008347:0.005627:0.010947:0.010947:0.004977:0.003250:0.010263:0.011340:0.008056:0.013735:0.011032:0.015873:0.015873:0.003250:0.005627:0.005627:0.010947:0.010947:0.004567:0.008056:0.007115:0.010263:0.010947:0.008056:0.003695:0.012555:0.008997:0.012486:0.008056:0.006140:0.003695:0.010263:0.005627:0.010947:0.004977:0.005679
national Duration Evaluation of Adjuvant :@0.560606:0.237991:0.919899:0.237991:0.919899:0.223986:0.560606:0.223986:0.010263:0.011511:0.005627:0.003250:0.011032:0.010263:0.011511:0.003250:0.010690:0.012555:0.010228:0.004977:0.011511:0.005627:0.003250:0.011032:0.010263:0.010690:0.008997:0.009305:0.011511:0.003250:0.010228:0.011511:0.005627:0.003250:0.011032:0.010263:0.010690:0.011032:0.005200:0.010690:0.012486:0.011545:0.003301:0.010228:0.009305:0.011511:0.010263:0.005797:0.004738
Chemotherapy) Collaboration: Prospec-:@0.560606:0.252302:0.915178:0.252302:0.915178:0.238297:0.560606:0.238297:0.013735:0.010263:0.010947:0.015873:0.011032:0.005627:0.010263:0.010947:0.004977:0.011511:0.011494:0.008997:0.006140:0.017429:0.013735:0.011032:0.003250:0.003250:0.011511:0.011494:0.011032:0.004977:0.011511:0.005627:0.003250:0.011032:0.010263:0.004567:0.017429:0.009955:0.004907:0.011032:0.006465:0.011494:0.010947:0.010895:0.005679
tive Combined Analysis of Phase III Trials :@0.560606:0.267060:0.919869:0.267060:0.919869:0.253055:0.560606:0.253055:0.005627:0.003250:0.009305:0.010947:0.010314:0.013735:0.011032:0.015873:0.011494:0.003250:0.010263:0.010947:0.011545:0.010314:0.012486:0.010263:0.011511:0.003250:0.008997:0.006465:0.003250:0.006465:0.010314:0.011032:0.005200:0.010314:0.009955:0.010263:0.011511:0.006465:0.010947:0.010314:0.003695:0.003695:0.003695:0.010314:0.006602:0.004977:0.003250:0.011511:0.003250:0.006640:0.004738
Investigating Duration of Adjuvant Therapy :@0.560606:0.281818:0.919919:0.281818:0.919919:0.267813:0.560606:0.267813:0.003695:0.010263:0.009305:0.010947:0.006465:0.005627:0.003250:0.011340:0.011511:0.005627:0.003250:0.010263:0.011340:0.006568:0.012555:0.010228:0.004977:0.011511:0.005627:0.003250:0.011032:0.010263:0.006568:0.011032:0.005200:0.006568:0.012486:0.011545:0.003301:0.010228:0.009305:0.011511:0.010263:0.005627:0.006568:0.007115:0.010263:0.010947:0.004977:0.011511:0.011494:0.009170:0.004738
with the FOLFOX (FOLFOX4 or Modified FOL-:@0.560606:0.296576:0.915188:0.296576:0.915188:0.282570:0.560606:0.282570:0.014043:0.003250:0.005627:0.010263:0.004604:0.005627:0.010263:0.010947:0.004606:0.008125:0.014693:0.007731:0.008125:0.014693:0.010246:0.004606:0.006140:0.008125:0.014693:0.007731:0.008125:0.014693:0.010246:0.009305:0.004604:0.011032:0.004977:0.004604:0.015548:0.011032:0.011545:0.003250:0.004079:0.004079:0.010947:0.011545:0.004606:0.008125:0.014693:0.007731:0.005679
FOX6) or XELOX (3 versus 6 months) Regimen :@0.560606:0.311334:0.919916:0.311334:0.919916:0.297328:0.560606:0.297328:0.008125:0.014693:0.010246:0.009305:0.006140:0.003763:0.011032:0.004977:0.003763:0.010246:0.008997:0.007731:0.014693:0.010246:0.003763:0.006140:0.009305:0.003763:0.009305:0.010947:0.004977:0.006465:0.010228:0.006465:0.003763:0.009305:0.003763:0.015873:0.011032:0.010263:0.005627:0.010263:0.006465:0.006140:0.003763:0.010211:0.010947:0.011340:0.003250:0.015873:0.010947:0.010432:0.004738
for Patients with Stage III Colon Cancer: Trial :@0.560606:0.326091:0.919938:0.326091:0.919938:0.312086:0.560606:0.312086:0.005200:0.011032:0.004977:0.004533:0.009955:0.011511:0.005627:0.003250:0.010947:0.010263:0.005627:0.006465:0.004533:0.014043:0.003250:0.005627:0.010263:0.004533:0.008347:0.005627:0.011511:0.011340:0.010947:0.004533:0.003695:0.003695:0.003695:0.004533:0.013735:0.011032:0.003250:0.011032:0.010263:0.004533:0.013735:0.011511:0.010263:0.010895:0.010947:0.004977:0.004567:0.004533:0.006602:0.004977:0.003250:0.011511:0.003424:0.004738
Design and Current Status. :@0.560606:0.340555:0.786370:0.340555:0.786370:0.326550:0.560606:0.326550:0.012555:0.010947:0.006465:0.003250:0.011340:0.010263:0.006609:0.011511:0.010263:0.011545:0.006611:0.013735:0.010228:0.004977:0.004907:0.010947:0.010263:0.005627:0.006609:0.008347:0.005627:0.011511:0.005627:0.010228:0.006465:0.004567:0.004738
Curr Colorectal :@0.788231:0.340555:0.919929:0.340555:0.919929:0.326550:0.788231:0.326550:0.013735:0.010228:0.004977:0.004977:0.006611:0.013735:0.011032:0.003250:0.011032:0.004977:0.010947:0.010895:0.005627:0.011511:0.003424:0.004738
Cancer Rep:@0.560606:0.355019:0.660325:0.355019:0.660325:0.341014:0.560606:0.341014:0.013735:0.011511:0.010263:0.010895:0.010947:0.004977:0.004567:0.010211:0.010947:0.011665
. 2013;9:261-269.:@0.660153:0.355019:0.791019:0.355019:0.791019:0.341014:0.660153:0.341014:0.004567:0.004567:0.009305:0.009305:0.009305:0.009305:0.004567:0.009305:0.004567:0.009305:0.009305:0.009305:0.005508:0.009305:0.009305:0.009305:0.004738
20.  Klastersky J, Raftopoulos H, Rapoport B. The :@0.524259:0.369483:0.919917:0.369483:0.919917:0.355478:0.524259:0.355478:0.009476:0.009476:0.004738:0.012657:0.000000:0.010109:0.003421:0.011682:0.006636:0.005798:0.011118:0.005148:0.006636:0.008586:0.009168:0.004293:0.008244:0.004738:0.004293:0.010382:0.011682:0.005371:0.005798:0.011203:0.011665:0.011203:0.010399:0.003421:0.011203:0.006636:0.004293:0.011682:0.004738:0.004293:0.010382:0.011682:0.011665:0.011203:0.011665:0.011203:0.005148:0.005798:0.004293:0.009818:0.004738:0.004293:0.007286:0.010434:0.011118:0.004738
MASCC Neutropenia, Infection and Myelo-:@0.560606:0.383947:0.915176:0.383947:0.915176:0.369942:0.560606:0.369942:0.015719:0.012657:0.008518:0.013906:0.013906:0.004430:0.012657:0.011118:0.010399:0.005798:0.005068:0.011203:0.011665:0.011118:0.010434:0.003421:0.011682:0.004738:0.004430:0.003866:0.010434:0.005371:0.011118:0.011067:0.005798:0.003421:0.011203:0.010434:0.004421:0.011682:0.010434:0.011716:0.004430:0.015719:0.009168:0.011118:0.003421:0.011203:0.005679
suppression Study Group evaluates recent :@0.560606:0.398411:0.919911:0.398411:0.919911:0.384406:0.560606:0.384406:0.006636:0.010399:0.011665:0.011665:0.005083:0.011118:0.006636:0.006636:0.003421:0.011203:0.010434:0.006217:0.008518:0.005798:0.010399:0.011716:0.009168:0.006217:0.014915:0.005078:0.011203:0.010399:0.011665:0.006212:0.011118:0.009476:0.011682:0.003421:0.010399:0.011682:0.005798:0.011118:0.006636:0.006216:0.005078:0.011118:0.011067:0.011118:0.010434:0.005798:0.004738
new  concepts  for  the  use  of  granulocyte :@0.560606:0.412875:0.919928:0.412875:0.919928:0.398869:0.560606:0.398869:0.010434:0.011118:0.014214:0.004738:0.002774:0.011067:0.011203:0.010434:0.011067:0.011118:0.011665:0.005798:0.006636:0.004738:0.002779:0.005371:0.011203:0.005148:0.004738:0.002774:0.005798:0.010434:0.011118:0.004738:0.002773:0.010399:0.006636:0.011118:0.004738:0.002778:0.011203:0.005371:0.004738:0.002774:0.011511:0.005148:0.011682:0.010434:0.010399:0.003421:0.011203:0.011067:0.009168:0.005798:0.011118:0.004738
colony-stimulating factors  for  the preven-:@0.560606:0.427339:0.915188:0.427339:0.915188:0.413333:0.560606:0.413333:0.011067:0.011203:0.003421:0.011203:0.010434:0.009168:0.005679:0.006636:0.005798:0.003421:0.016044:0.010399:0.003421:0.011682:0.005798:0.003421:0.010434:0.011511:0.008330:0.005371:0.011682:0.011067:0.005798:0.011203:0.005148:0.006636:0.004738:0.003580:0.005371:0.011203:0.005148:0.004738:0.003578:0.005798:0.010434:0.011118:0.008330:0.011665:0.005080:0.011118:0.009476:0.011118:0.010434:0.005679
tion  of  febrile neutropenia. :@0.560606:0.441803:0.796651:0.441803:0.796651:0.427797:0.560606:0.427797:0.005798:0.003421:0.011203:0.010434:0.004738:0.003768:0.011203:0.005371:0.004738:0.003770:0.005371:0.011118:0.011665:0.005148:0.003421:0.003421:0.011118:0.008518:0.010434:0.011118:0.010399:0.005798:0.005073:0.011203:0.011665:0.011118:0.010434:0.003421:0.011682:0.004738:0.004738
Support  Care :@0.800409:0.441803:0.919905:0.441803:0.919905:0.427797:0.800409:0.427797:0.008518:0.010399:0.011665:0.011665:0.011203:0.005148:0.005798:0.004738:0.003768:0.013906:0.011682:0.005148:0.011118:0.004738
Cancer.:@0.560606:0.456266:0.628699:0.456266:0.628699:0.442261:0.560606:0.442261:0.013906:0.011682:0.010434:0.011067:0.011118:0.005148:0.004738
 2013 Jun;21(6):1793-5.:@0.628681:0.456266:0.811749:0.456266:0.811749:0.442261:0.628681:0.442261:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.008244:0.010399:0.010434:0.004738:0.009476:0.007765:0.006312:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476:0.004738
21.  Klastersky J, de Naurois J, Rolston K, :@0.524242:0.470730:0.869196:0.470730:0.869196:0.456725:0.524242:0.456725:0.009476:0.009476:0.004738:0.012657:0.000000:0.010109:0.003421:0.011682:0.006636:0.005798:0.011118:0.005148:0.006636:0.008586:0.009168:0.006961:0.008244:0.004738:0.006961:0.011716:0.011118:0.006961:0.012657:0.011682:0.010399:0.005073:0.011203:0.003421:0.006636:0.006961:0.008244:0.004738:0.006961:0.010382:0.011203:0.003421:0.006636:0.005798:0.011203:0.010434:0.006961:0.010109:0.004738:0.004738
et al.:@0.871420:0.470730:0.915138:0.470730:0.915138:0.456725:0.871420:0.456725:0.011118:0.005798:0.006961:0.011682:0.003421:0.004738
 :@0.915138:0.470730:0.919876:0.470730:0.919876:0.456725:0.915138:0.456725:0.004738
ESMO Guidelines Committee.  Manage-:@0.560589:0.485194:0.915147:0.485194:0.915147:0.471189:0.560589:0.471189:0.009168:0.008518:0.015719:0.014864:0.014231:0.014915:0.010399:0.003421:0.011716:0.011118:0.003421:0.003421:0.010434:0.011118:0.006636:0.014231:0.013906:0.011203:0.016044:0.016044:0.003421:0.005798:0.005798:0.011118:0.011118:0.004738:0.004738:0.009478:0.015719:0.011682:0.010434:0.011682:0.011511:0.011118:0.005679
ment of febrile neutropaenia: ESMO Clini-:@0.560589:0.499658:0.915135:0.499658:0.915135:0.485653:0.560589:0.485653:0.016044:0.011118:0.010434:0.005798:0.007201:0.011203:0.005371:0.007201:0.005371:0.011118:0.011665:0.005148:0.003421:0.003421:0.011118:0.007201:0.010434:0.011118:0.010399:0.005798:0.005070:0.011203:0.011665:0.011682:0.011118:0.010434:0.003421:0.011682:0.004738:0.007201:0.009168:0.008518:0.015719:0.014864:0.007201:0.013906:0.003421:0.003421:0.010434:0.003421:0.005679
cal Practice Guidelines:@0.560589:0.514122:0.758965:0.514122:0.758965:0.500117:0.560589:0.500117:0.011067:0.011682:0.003421:0.008090:0.010126:0.005148:0.011682:0.011067:0.005798:0.003421:0.011067:0.011118:0.008090:0.014915:0.010399:0.003421:0.011716:0.011118:0.003421:0.003421:0.010434:0.011118:0.006636
. Ann Oncol:@0.758965:0.514122:0.864397:0.514122:0.864397:0.500117:0.758965:0.500117:0.004738:0.008090:0.012657:0.010434:0.010434:0.008090:0.014864:0.010434:0.011067:0.011203:0.003421
. 2016 :@0.864397:0.514122:0.919866:0.514122:0.919866:0.500117:0.864397:0.500117:0.004738:0.008090:0.009476:0.009476:0.009476:0.009476:0.004738
Sep;27(suppl 5):v111-v118.:@0.560589:0.528586:0.777164:0.528586:0.777164:0.514581:0.560589:0.514581:0.008518:0.011118:0.011665:0.004738:0.009476:0.009476:0.006312:0.006636:0.010399:0.011665:0.011665:0.003421:0.004738:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.009476:0.004738
22.  Rapoport BL, Sussmann O, Herrera MV, :@0.524242:0.543050:0.895574:0.543050:0.895574:0.529044:0.524242:0.529044:0.009476:0.009476:0.004738:0.012657:0.000000:0.010382:0.011682:0.011665:0.011203:0.011665:0.011203:0.005148:0.005798:0.007406:0.009818:0.007902:0.004738:0.007406:0.008518:0.010399:0.006636:0.006636:0.016044:0.011682:0.010434:0.010434:0.007406:0.014864:0.004738:0.007406:0.011682:0.011118:0.005148:0.005073:0.011118:0.005148:0.011682:0.007406:0.015719:0.010198:0.004738:0.004738
et :@0.898243:0.543050:0.919897:0.543050:0.919897:0.529044:0.898243:0.529044:0.011118:0.005798:0.004738
al:@0.560589:0.557514:0.575692:0.557514:0.575692:0.543508:0.560589:0.543508:0.011682:0.003421
.  Ceftriaxone  plus once  daily aminogly-:@0.575692:0.557514:0.915140:0.557514:0.915140:0.543508:0.575692:0.543508:0.004738:0.004738:0.003139:0.013906:0.011118:0.005371:0.005798:0.005148:0.003421:0.011682:0.008210:0.011203:0.010434:0.011118:0.004738:0.003130:0.011665:0.003421:0.010399:0.006636:0.007885:0.011203:0.010434:0.011067:0.011118:0.004738:0.003134:0.011716:0.011682:0.003421:0.003421:0.009168:0.007885:0.011682:0.016044:0.003421:0.010434:0.011203:0.011511:0.003421:0.009168:0.005679
coside  with  filgrastim  for  treatment  of  fe-:@0.560589:0.571978:0.915159:0.571978:0.915159:0.557972:0.560589:0.557972:0.011067:0.011203:0.006636:0.003421:0.011716:0.011118:0.004738:0.003636:0.014214:0.003421:0.005798:0.010434:0.004738:0.003633:0.004165:0.004165:0.003421:0.011511:0.005148:0.011682:0.006636:0.005798:0.003421:0.016044:0.004738:0.003638:0.005371:0.011203:0.005148:0.004738:0.003626:0.005798:0.005075:0.011118:0.011682:0.005798:0.016044:0.011118:0.010434:0.005798:0.004738:0.003630:0.011203:0.005371:0.004738:0.003630:0.005371:0.011118:0.005679
brile neutropenia: early hospital discharge :@0.560589:0.586441:0.919907:0.586441:0.919907:0.572436:0.560589:0.572436:0.011665:0.005148:0.003421:0.003421:0.011118:0.006294:0.010434:0.011118:0.010399:0.005798:0.005077:0.011203:0.011665:0.011118:0.010434:0.003421:0.011682:0.004738:0.006286:0.011118:0.011682:0.005148:0.003421:0.009168:0.006294:0.010434:0.011203:0.006636:0.011665:0.003421:0.005798:0.011682:0.003421:0.006294:0.011716:0.003421:0.006636:0.011067:0.010434:0.011682:0.005167:0.011511:0.011118:0.004738
vs. standard  in-patient  care. :@0.560589:0.600905:0.834649:0.600905:0.834649:0.586900:0.560589:0.586900:0.009476:0.006636:0.004738:0.016882:0.006636:0.005798:0.011682:0.010434:0.011716:0.011682:0.005046:0.011716:0.004738:0.012136:0.003421:0.010434:0.005679:0.011665:0.011682:0.005798:0.003421:0.011118:0.010434:0.005798:0.004738:0.012132:0.011067:0.011682:0.005080:0.011118:0.004738:0.004738
Chemo- :@0.846779:0.600905:0.919900:0.600905:0.919900:0.586900:0.846779:0.586900:0.013906:0.010434:0.011118:0.016044:0.011203:0.005679:0.004738
therapy.:@0.560589:0.615369:0.630341:0.615369:0.630341:0.601364:0.560589:0.601364:0.005798:0.010434:0.011118:0.005148:0.011682:0.011665:0.009168:0.004738
1999 Nov-Dec;45(6):466-76.:@0.630341:0.615369:0.855229:0.615369:0.855229:0.601364:0.630341:0.601364:0.009476:0.009476:0.009476:0.009476:0.004738:0.012657:0.011203:0.009476:0.005679:0.012726:0.011118:0.011067:0.004738:0.009476:0.009476:0.006312:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.004738
23.  van Eeden R, Rapoport  BL.Current trends :@0.524242:0.629833:0.919895:0.629833:0.919895:0.615828:0.524242:0.615828:0.009476:0.009476:0.004738:0.012657:0.000000:0.009476:0.011682:0.010434:0.008090:0.009168:0.011118:0.011716:0.011118:0.010434:0.008090:0.010382:0.004738:0.008090:0.010382:0.011682:0.011665:0.011203:0.011665:0.011203:0.005148:0.005798:0.004738:0.003344:0.009818:0.007902:0.004738:0.013906:0.010399:0.005148:0.005071:0.011118:0.010434:0.005798:0.008090:0.005798:0.005075:0.011118:0.010434:0.011716:0.006636:0.004738
in the management of anaemia in solid :@0.560589:0.644297:0.919883:0.644297:0.919883:0.630292:0.560589:0.630292:0.003421:0.010434:0.009100:0.005798:0.010434:0.011118:0.009100:0.016044:0.011682:0.010434:0.011682:0.011511:0.011118:0.016044:0.011118:0.010434:0.005798:0.009100:0.011203:0.005371:0.009100:0.011682:0.010434:0.011682:0.011118:0.016044:0.003421:0.011682:0.009100:0.003421:0.010434:0.009100:0.006636:0.011203:0.003421:0.003421:0.011716:0.004738
tumours and haematological malignan-:@0.560589:0.658761:0.915145:0.658761:0.915145:0.644756:0.560589:0.644756:0.005798:0.010399:0.016044:0.011203:0.010399:0.005148:0.006636:0.012366:0.011682:0.010434:0.011716:0.012366:0.010434:0.011682:0.011118:0.016044:0.011682:0.005798:0.011203:0.003421:0.011203:0.011511:0.003421:0.011067:0.011682:0.003421:0.012366:0.016044:0.011682:0.003421:0.003421:0.011511:0.010434:0.011682:0.010434:0.005679
cies. :@0.560589:0.673225:0.602307:0.673225:0.602307:0.659219:0.560589:0.659219:0.011067:0.003421:0.011118:0.006636:0.004738:0.004738
Curr Opin Support Palliat  Care.:@0.604923:0.673225:0.869880:0.673225:0.869880:0.659219:0.604923:0.659219:0.013906:0.010399:0.005148:0.005148:0.007355:0.014864:0.011665:0.003421:0.010434:0.007355:0.008518:0.010399:0.011665:0.011665:0.011203:0.005148:0.005798:0.007355:0.010126:0.011682:0.003421:0.003421:0.003421:0.011682:0.005798:0.004738:0.002627:0.013906:0.011682:0.005148:0.011118:0.004738
 2016 :@0.869880:0.673225:0.919876:0.673225:0.919876:0.659219:0.869880:0.659219:0.007355:0.009476:0.009476:0.009476:0.009476:0.004738
Jun;10(2):189-94.:@0.560589:0.687689:0.697988:0.687689:0.697988:0.673683:0.560589:0.673683:0.008244:0.010399:0.010434:0.004738:0.009476:0.009476:0.006312:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.004738
24.  Apelseth TO, Hervig T, Bruserud O. Current :@0.524242:0.702153:0.919888:0.702153:0.919888:0.688147:0.524242:0.688147:0.009476:0.009476:0.004738:0.012657:0.000000:0.012657:0.011665:0.011118:0.003421:0.006636:0.011118:0.005798:0.010434:0.006722:0.007286:0.014864:0.004738:0.006722:0.011682:0.011118:0.005148:0.009476:0.003421:0.011511:0.006722:0.005538:0.004738:0.006722:0.009818:0.005148:0.010399:0.006636:0.011118:0.005148:0.010399:0.011716:0.006722:0.014864:0.004738:0.006722:0.013906:0.010399:0.005148:0.005071:0.011118:0.010434:0.005798:0.004738
practice and future directions for optimiza-:@0.560589:0.716616:0.915149:0.716616:0.915149:0.702611:0.560589:0.702611:0.011665:0.005148:0.011682:0.011067:0.005798:0.003421:0.011067:0.011118:0.004762:0.011682:0.010434:0.011716:0.004764:0.005371:0.010399:0.005798:0.010399:0.005071:0.011118:0.004762:0.011716:0.003421:0.005083:0.011118:0.011067:0.005798:0.003421:0.011203:0.010434:0.006636:0.004758:0.005371:0.011203:0.005148:0.004755:0.011203:0.011665:0.005798:0.003421:0.016044:0.003421:0.007269:0.011682:0.005679
tion of platelet transfusions in patients with :@0.560589:0.731080:0.919907:0.731080:0.919907:0.717075:0.560589:0.717075:0.005798:0.003421:0.011203:0.010434:0.005836:0.011203:0.005371:0.005836:0.011665:0.003421:0.011682:0.005798:0.011118:0.003421:0.011118:0.005798:0.005850:0.005798:0.005148:0.011682:0.010434:0.006636:0.005371:0.010399:0.006636:0.003421:0.011203:0.010434:0.006636:0.005850:0.003421:0.010434:0.005841:0.011665:0.011682:0.005798:0.003421:0.011118:0.010434:0.005798:0.006636:0.005841:0.014214:0.003421:0.005798:0.010434:0.004738
severe therapy-induced cytopenia. :@0.560589:0.745544:0.865271:0.745544:0.865271:0.731539:0.560589:0.731539:0.006636:0.011118:0.009476:0.011118:0.005082:0.011118:0.007269:0.005798:0.010434:0.011118:0.005148:0.011682:0.011665:0.009168:0.005679:0.003421:0.010434:0.011716:0.010399:0.011067:0.011118:0.011716:0.007269:0.011067:0.009168:0.005798:0.011203:0.011665:0.011118:0.010434:0.003421:0.011682:0.004738:0.004738
Blood :@0.867802:0.745544:0.919902:0.745544:0.919902:0.731539:0.867802:0.731539:0.009818:0.003421:0.011203:0.011203:0.011716:0.004738
Rev:@0.560589:0.760008:0.591565:0.760008:0.591565:0.746003:0.560589:0.746003:0.010382:0.011118:0.009476
. 2011 May;25(3):113-22.:@0.591565:0.760008:0.788573:0.760008:0.788573:0.746003:0.591565:0.746003:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.015719:0.011682:0.009168:0.004738:0.009476:0.009476:0.006312:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.004738
25.  Jordan K, Chan A, Gralla RJ, :@0.524242:0.774766:0.819251:0.774766:0.819251:0.760761:0.524242:0.760761:0.009476:0.009476:0.004738:0.012657:0.000000:0.008244:0.011203:0.005039:0.011716:0.011682:0.010434:0.008655:0.010109:0.004738:0.008655:0.013906:0.010434:0.011682:0.010434:0.008655:0.012657:0.004738:0.008655:0.014915:0.005148:0.011682:0.003421:0.003421:0.011682:0.008655:0.010382:0.008244:0.004738:0.004738
et al:@0.823168:0.774766:0.863842:0.774766:0.863842:0.760761:0.823168:0.760761:0.011118:0.005798:0.008655:0.011682:0.003421
. 2016 :@0.863842:0.774766:0.919876:0.774766:0.919876:0.760761:0.863842:0.760761:0.004738:0.008655:0.009476:0.009476:0.009476:0.009476:0.004738
Updated MASCC/ESMO consensus recom-:@0.560589:0.789524:0.915159:0.789524:0.915159:0.775519:0.560589:0.775519:0.011203:0.011665:0.011716:0.011682:0.005798:0.011118:0.011716:0.004823:0.015719:0.012657:0.008518:0.013906:0.013906:0.007475:0.009168:0.008518:0.015719:0.014864:0.004823:0.011067:0.011203:0.010434:0.006636:0.011118:0.010434:0.006636:0.010399:0.006636:0.004823:0.005077:0.011118:0.011067:0.011203:0.016044:0.005679
mendations:  emetic  risk  classification  and :@0.560589:0.804282:0.919890:0.804282:0.919890:0.790276:0.560589:0.790276:0.016044:0.011118:0.010434:0.011716:0.011682:0.005798:0.003421:0.011203:0.010434:0.006636:0.004738:0.004738:0.002843:0.011118:0.016044:0.011118:0.005798:0.003421:0.011067:0.004738:0.002848:0.005148:0.003421:0.006636:0.008586:0.004738:0.002851:0.011067:0.003421:0.011682:0.006636:0.006636:0.003421:0.004165:0.004165:0.011067:0.011694:0.005798:0.003421:0.011203:0.010434:0.004738:0.002844:0.011682:0.010434:0.011716:0.004738
evaluation of the emetogenicity of anti-:@0.560589:0.819040:0.915152:0.819040:0.915152:0.805034:0.560589:0.805034:0.011118:0.009476:0.011682:0.003421:0.010399:0.011682:0.005798:0.003421:0.011203:0.010434:0.009442:0.011203:0.005371:0.009442:0.005798:0.010434:0.011118:0.009442:0.011118:0.016044:0.011118:0.005798:0.011203:0.011511:0.011118:0.010434:0.003421:0.011067:0.003421:0.005798:0.009158:0.009442:0.011203:0.005371:0.009442:0.011682:0.010434:0.005798:0.003421:0.005679
neoplastic agents. :@0.560589:0.833797:0.721661:0.833797:0.721661:0.819792:0.560589:0.819792:0.010434:0.011118:0.011203:0.011665:0.003421:0.011682:0.006636:0.005798:0.003421:0.011067:0.007971:0.011682:0.011511:0.011118:0.010434:0.005798:0.006636:0.004738:0.004738
Support Care Cancer:@0.724893:0.833797:0.910442:0.833797:0.910442:0.819792:0.724893:0.819792:0.008518:0.010399:0.011665:0.011665:0.011203:0.005148:0.005798:0.007971:0.013906:0.011682:0.005148:0.011118:0.007971:0.013906:0.011682:0.010434:0.011067:0.011118:0.005148
. :@0.910442:0.833797:0.919917:0.833797:0.919917:0.819792:0.910442:0.819792:0.004738:0.004738
2017 Jan;25(1):271-275.:@0.560589:0.848555:0.751388:0.848555:0.751388:0.834550:0.560589:0.834550:0.009476:0.009476:0.009476:0.009476:0.004738:0.008244:0.011682:0.010434:0.004738:0.009476:0.009476:0.006312:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.004738
26.  Olver I, Ruhlmann CH, Jahn F, :@0.524242:0.863313:0.821992:0.863313:0.821992:0.849308:0.524242:0.849308:0.009476:0.009476:0.004738:0.012657:0.000000:0.014864:0.003421:0.009476:0.011118:0.005148:0.007748:0.003866:0.004738:0.007748:0.010382:0.010399:0.010434:0.003421:0.016044:0.011682:0.010434:0.010434:0.007748:0.013906:0.011682:0.004738:0.007748:0.008244:0.011682:0.010434:0.010434:0.007748:0.006205:0.004738:0.004738
et al.:@0.825002:0.863313:0.869507:0.863313:0.869507:0.849308:0.825002:0.849308:0.011118:0.005798:0.007748:0.011682:0.003421:0.004738
 2016 :@0.869507:0.863313:0.919897:0.863313:0.919897:0.849308:0.869507:0.849308:0.007748:0.009476:0.009476:0.009476:0.009476:0.004738
Updated MASCC/ESMO Consensus Rec-:@0.560589:0.878071:0.915145:0.878071:0.915145:0.864066:0.560589:0.864066:0.011203:0.011665:0.011716:0.011682:0.005798:0.011118:0.011716:0.011186:0.015719:0.012657:0.008518:0.013906:0.013906:0.007475:0.009168:0.008518:0.015719:0.014864:0.011186:0.013906:0.011203:0.010434:0.006636:0.011118:0.010434:0.006636:0.010399:0.006636:0.011186:0.010382:0.011118:0.011067:0.005679
ommendations:  controlling  nausea  and :@0.560589:0.892829:0.919888:0.892829:0.919888:0.878824:0.560589:0.878824:0.011203:0.016044:0.016044:0.011118:0.010434:0.011716:0.011682:0.005798:0.003421:0.011203:0.010434:0.006636:0.004738:0.004738:0.009029:0.011067:0.011203:0.010434:0.005798:0.005070:0.011203:0.003421:0.003421:0.003421:0.010434:0.011511:0.004738:0.009040:0.010434:0.011682:0.010399:0.006636:0.011118:0.011682:0.004738:0.009040:0.011682:0.010434:0.011716:0.004738
vomiting with chemotherapy of low or mini-:@0.560589:0.907587:0.915166:0.907587:0.915166:0.893582:0.560589:0.893582:0.009476:0.011203:0.016044:0.003421:0.005798:0.003421:0.010434:0.011511:0.003960:0.014214:0.003421:0.005798:0.010434:0.003968:0.011067:0.010434:0.011118:0.016044:0.011203:0.005798:0.010434:0.011118:0.005148:0.011682:0.011665:0.009168:0.003955:0.011203:0.005371:0.003956:0.003421:0.011203:0.014214:0.003968:0.011203:0.005148:0.003955:0.016044:0.003421:0.010434:0.003421:0.005679
mal emetic potential. :@0.560589:0.921898:0.749370:0.921898:0.749370:0.907893:0.560589:0.907893:0.016044:0.011682:0.003421:0.007526:0.011118:0.016044:0.011118:0.005798:0.003421:0.011067:0.007526:0.011665:0.011203:0.005798:0.011118:0.010434:0.005798:0.003421:0.011682:0.003421:0.004738:0.004738
Support Care Can-:@0.752158:0.921898:0.915162:0.921898:0.915162:0.907893:0.752158:0.907893:0.008518:0.010399:0.011665:0.011665:0.011203:0.005148:0.005798:0.007526:0.013906:0.011682:0.005148:0.011118:0.007526:0.013906:0.011682:0.010434:0.005679
cer. :@0.560589:0.936209:0.597398:0.936209:0.597398:0.922204:0.560589:0.922204:0.011067:0.011118:0.005148:0.004738:0.004738
2017 Jan;25(1):297-301.:@0.597380:0.936209:0.788180:0.936209:0.788180:0.922204:0.597380:0.922204:0.009476:0.009476:0.009476:0.009476:0.004738:0.008244:0.011682:0.010434:0.004738:0.009476:0.009476:0.006312:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.004738